Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Inclusion Criteria: * STEP 1 (PROBANDS): Speaks and/or reads English or Spanish * STEP 1 (PROBANDS): Currently receiving diagnostic, treatment, or follow-up care in the outpatient gynecologic oncology and medical oncology clinics at LBJ * STEP 1 (PROBANDS): Has completed genetic counseling, with pedigree available in the medical record (LBJ) * STEP 1 (PROBANDS): Diagnosed with female-breast, ovarian, fallopian tube, primary peritoneal, endometrial cancer on or after January 1, 2014 * STEP 1 (PROBANDS): Has a confirmed deleterious or suspected deleterious (pathogenic) variant in a hereditary gynecologic or breast cancer predisposition gene (including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, BRIP1, PALB2, RAD51C, RAD51D, STK11, DICER1, SMARCA4, ATM, CHEK2, PTEN, TP53, CDH1, BARD1) * STEP 1 (FIRST-DEGREE RELATIVE \[FDR\]): Speaks and/or reads English or Spanish * STEP 1 (FDR): Is a first-degree relative of proband (son, daughter, full-brother, full-sister, mother, father) * STEP 1 (FDR): Is present with proband at time of recruitment, or can be contacted by telephone via a United States (U.S.) telephone number * STEP 1 (FDR): Is aware of proband's genetic testing result/mutation status, per proband report * STEP 2 (PROBANDS): Speaks or reads English or Spanish * STEP 2 (PROBANDS): Currently receives diagnostic, treatment, or follow-up care for female-breast cancer in the outpatient medical oncology clinics at LBJ; or currently receives diagnostic, treatment, or follow-up ca…